[A remarkable effect of K-18 (IgG-melphalan complex) in a case of RAEB with hypoplastic marrow].
A 63-year-old male with refractory anemia with excess of blasts (RAEB) and hypoplastic marrow was treated with K-18 (240 mg/day P.O.). On admission, peripheral blood revealed pancytopenia. Bone marrow specimen revealed severe hypocellularity with 18.9% of the blast cells. Ten months later, the blast cells in the bone marrow decreased to 3.8%, and complete remission (CR) was obtained. CR was eight weeks. Duration of response (CR + PR) continued for about eight months. K-18 is an antitumor agent with minimal side effects, and seems to be effective for RAEB with hypoplastic marrow.
Fujikawa
K
K
Dept. of Internal Medicine (Section 4), Sapporo Medical College.
Mogi
Y
Y
Ito
K
K
Tsushima
N
N
Saito
T
T
Ishigaki
S
S
Watanabe
N
N
Kohgo
Y
Y
Mikami
T
T
Niitsu
Y
Y
D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D012074:Remission Induction
D007074:Immunoglobulin G; C051713:antineoplastic agent K 18; D008558:Melphalan